Morphic Therapeutic

Morphic Therapeutic

  • Founded: 2016
  • Location: Waltham, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Ulcerative colitis, Crohn's
  • Drug types: GI, ONC, CVV
  • Lead product: MORF-057
  • Product link:
  • Funding: $240M stock May 2023; $245M stock Mar 2021; $90M IPO Jun 2019; $80M B Sep 2018; $51.5M A Jul 2016

job board

Short description:

Oral Integrin Drugs

Drug notes:

4 undisclosed programs RD/Clin0 GI conditions, solid tumors, fibrotic conditions, PAH, undisclosed

Long description:

Morphic Therapeutic is developing a new generation of oral integrin therapies to treat autoimmune, cardiovascular and metabolic diseases. Integrins are receptors found at the cell membrane and are involved in many cellular processes by signaling bi-directionally. Malfunctions in the integrins are linked with disease. Using their proprietary MInT drug discovery platform and knowledge from integrin research leaders, Morphic is in the position to target all 24 known human integrins to stabilize their conformation or to activate or inhibit their activity to modify disease. One molecule (MORF-057) is already in Phase I clinical trials for inflammatory bowel disease.


Morphic Therapeutic
Senior Director/ Executive Director, Clinical Phar...
Waltham, MA|28 days ago
Morphic Therapeutic
Vice President, Program Leadership
Waltham, MA|35 days ago
Morphic Therapeutic
Principal/Senior Scientist, (Clinical) Translation...
Waltham, MA|77 days ago
Morphic Therapeutic
(Senior/Exec) Medical Director, Gastroenterology
Waltham, MA|100+ days ago

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy